Regeneron Pharmaceuticals Inc (REGN34)

B3
Currency in BRL
64.71
-0.33(-0.51%)
Closed

REGN34 Income Statement

Advanced Income Statement
Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa8,497.116,071.712,172.913,117.214,202
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+29.58%+89.14%-24.26%+7.76%+8.27%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa3,766.95,297.65,152.96,254.87,102.5
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa4,730.210,774.17,0206,862.47,099.5
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+41.52%+127.77%-34.84%-2.25%+3.46%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa55.67%67.04%57.67%52.32%49.99%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa1,065.61,779.32,0262,629.22,954.4
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-5.92%+66.98%+13.87%+29.77%+12.37%
aa.aaaa.aaaa.aaaa.aaaa.aa-----
aa.aaaa.aaaa.aaaa.aaaa.aa1,3461,824.92,115.92,631.32,954.4
aa.aaaa.aaaa.aaaa.aaaa.aa-280.4-45.6-89.9-2.1-
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa3,664.68,994.84,9944,233.24,145.1
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+65.83%+145.45%-44.48%-15.23%-2.08%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa43.13%55.97%41.03%32.27%29.19%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa18.5-11.5100.7422.9656.2
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+161.26%-162.16%+975.65%+319.96%+55.17%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-56.9-57.3-59.4-73-55.2
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa75.445.8160.1495.9711.4
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa19.34.459-32.915.3
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa3,702.48,987.75,153.74,623.24,816.6
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-88-48-255.1-186.1-154.4
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa3,810.49,325.84,858.84,199.34,779.9
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+56.86%+144.75%-47.9%-13.57%+13.83%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa44.84%58.03%39.91%32.01%33.66%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa297.21,250.5520.4245.7367.3
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa3,513.28,075.34,338.43,953.64,412.6
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa3,513.28,075.34,338.43,953.64,412.6
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+66.05%+129.86%-46.28%-8.87%+11.61%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa41.35%50.25%35.64%30.14%31.07%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa3,513.28,075.34,338.43,953.64,412.6
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa32.6576.440.5137.0540.9
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+68.52%+133.99%-46.98%-8.53%+10.37%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa30.5271.9738.2234.7738.34
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+65.33%+135.81%-46.89%-9.03%+10.27%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa107.6105.7107.1106.7107.9
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa115.1112.2113.5113.7115.1
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa3,900.59,2815,335.44,654.24,628
EBITDA Growth
aa.aaaa.aaaa.aa